Cardinal Health, Inc. vs The Coca-Cola Company: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and The Coca-Cola Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating The Coca-Cola Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and The Coca-Cola Company is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $47.9B for The Coca-Cola Company, while their respective market capitalizations stand at $56.0B and $379.0B. Both Cardinal Health, Inc. and The Coca-Cola Company are headquartered in United States, so they compete in a shared home market and regulatory environment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

The Coca-Cola Company: The Coca-Cola Company (NYSE: KO), headquartered in Atlanta, is the world's largest nonalcoholic beverage company. It owns more than 200 brands, including Coca-Cola, Sprite, Fanta, Smartwater, Powerade, Minute Maid, Costa Coffee, BodyArmor and fairlife. For the most part it does not bottle its own drinks. It owns the trademarks and formulas, runs global marketing, and sells concentrate to a network of bottling partners that make and distribute finished beverages in more than 200 countries and territories. The company reported $47.9 billion in 2025 revenue and had about 65,900 employees at year-end. Henrique Braun has been CEO since March 31, 2026.

Cardinal Health, Inc. and The Coca-Cola Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and The Coca-Cola Company.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The Coca-Cola Company business model: Coca-Cola runs a franchise model. The company develops or acquires beverage recipes and runs global marketing, including sponsorships such as the Olympics. It earns revenue by selling concentrate to independent bottling companies around the world, such as Coca-Cola Europacific Partners. The bottlers add water, package the drinks and handle distribution, and pay Coca-Cola for the right to sell its brands.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of The Coca-Cola Company.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

The Coca-Cola Company competitive advantage: Coca-Cola's advantage is its brand and its distribution network. Its products reach even very remote places through a system of bottlers, trucks and independent shopkeepers that took more than a century to build. A new drinks company can develop a product people like, but it cannot quickly match Coca-Cola's reach into shops and refrigerators worldwide.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and The Coca-Cola Company each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

The Coca-Cola Company growth strategy: Coca-Cola calls itself a 'total beverage company': it keeps trademark Coca-Cola and Coca-Cola Zero Sugar at the center while building scale in coffee (Costa), sports hydration (BodyArmor, Powerade), premium water (Smartwater, Topo Chico) and value-added dairy (fairlife). Revenue growth management, meaning pack sizes, price tiers and mini-cans tuned to each market, is the main lever for growth without heavy volume gains. Alcohol-adjacent ready-to-drink products such as Jack Daniel's & Coca-Cola are produced with partners rather than on Coca-Cola's own books. The company also keeps refranchising bottlers: in October 2025 it agreed to sell a 41.52% stake in Coca-Cola Beverages Africa to Coca-Cola HBC for about $1.3 billion, a deal targeted to close by the end of 2026. In January 2026 it reportedly dropped a plan to sell Costa Coffee after private-equity bids fell short of its price.

A closer look at the financial trajectory of Cardinal Health, Inc. and The Coca-Cola Company rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

The Coca-Cola Company: Coca-Cola's financial profile comes from its asset-light franchise model. It sells concentrates and syrups to independent bottlers, which own the capital-intensive plants, trucks and coolers, so the parent company keeps high margins on a relatively small asset base. FY2025 revenue was $47.941 billion with $13.107 billion in net income, up from $47.061 billion in revenue in 2024. In Q2 2026, net revenue grew 7% to $13.4 billion and comparable EPS rose 11% to $0.97. That cash supports the dividend: in February 2026 the board approved a 64th consecutive annual increase, to $0.53 per quarter. Berkshire Hathaway has held 400 million shares since the early 1990s, making it the largest single shareholder.